Abemaciclib prolongs survival in HR+/HER2 negative advanced breast cancer

September 2020 Pharma News Ariez

Abemaciclib is an oral, selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is indicated for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. In previous reports of the phase III MONARCH 2 trial, the addition of abemaciclib to fulvestrant was shown to result in a significant improvement of the progression-free (PFS) and overall survival (OS) of women with HR+/HER2- advanced breast cancer and significantly delayed the time to the initiation of chemotherapy. In recent months, Professor Patrick Neven (University Hospitals Leuven) presented two interesting exploratory analyses of this trial.

DOWNLOAD PAPER: ‘Adding abemaciclib to fulvestrant delays disease progression and prolongs the survival of women with HR+/HER2 negative advanced breast cancer across treatment lines, with a particularly pronounced survival benefit in patients with poor prognostic features’